Targeted Therapy in Inflammatory Bowel Disease; Current Status and Future Perspectives.
- Author:
Byung Ik JANG
1
Author Information
- Publication Type:Review
- Keywords: Inflammatory Bowel Diseases; Therapeutics; Tumor Necrosis Factor-alpha; Biological Agents
- MeSH: Antibodies, Monoclonal, Humanized; Antibody Formation; Biological Agents; Biological Therapy; Cytokines; Humans; Inflammatory Bowel Diseases; Intercellular Signaling Peptides and Proteins; Interleukin-17; Phosphorothioate Oligonucleotides; Protein Kinases; T-Lymphocytes; Tumor Necrosis Factor-alpha; Natalizumab
- From:Hanyang Medical Reviews 2012;32(2):94-102
- CountryRepublic of Korea
- Language:Korean
- Abstract: Novel biologic agents that selectively target specific molecules and pathways have been developed recently for the management of inflammatory bowel disease (IBD). Anti-TNF-alpha, an antibody to TNF-alpha is one of the first newly developed drugs to dramatically improve the symptoms of patients with IBD. Therapy with anti-TNF-alpha demonstrates a new paradigm for management of IBD and early treatment with these drugs has demonstrated increased benefit. However, more than one-third of the patients have lost response to the drug. Also, there is the problem of antibody formation. Therefore, enormous efforts to develop novel drugs as an alternatives to anti-TNF-alpha are underway. Anti CD4+ T cell cytokine including IL-12/23 and IL-17 blockers, selective anti-adhesion molecules known as natalizumab, vedolizumab and alicaforsen, T-cell proliferation inhibitors, anti-inflammatory cytokines, immune stimulators, growth factors and mitogen activated protein kinase (MAPK) inhibitors are among the novel therapeutic agents that are currently being investigated for efficacy and safety in the management of IBD. The aim of this paper is to review current knowledge concerning the mechanism of action, the short and long term efficacy, and the safety of these novel biologic therapies, as well as that of anti-TNF-alpha, in IBD.
